1 2116 130 EPIGENETIC HISTONE DEACETYLATION INHIBITION PREVENTS THE DEVELOPMENT AND PERSISTENCE OF TEMPORAL LOBE EPILEPSY. EPILEPSY IS A CHRONIC BRAIN DISEASE CHARACTERIZED BY REPEATED UNPROVOKED SEIZURES. CURRENTLY, NO DRUG THERAPY EXISTS FOR CURING EPILEPSY OR DISEASE MODIFICATION IN PEOPLE AT RISK. DESPITE SEVERAL EMERGING MECHANISMS, THERE HAVE BEEN FEW STUDIES OF EPIGENETIC SIGNALING IN EPILEPTOGENESIS, THE PROCESS WHEREBY A NORMAL BRAIN BECOMES PROGRESSIVELY EPILEPTIC BECAUSE OF PRECIPITATING FACTORS. HERE, WE REPORT A NOVEL ROLE OF HISTONE DEACETYLATION AS A CRITICAL EPIGENETIC MECHANISM IN EPILEPTOGENESIS. EXPERIMENTS WERE CONDUCTED USING THE HISTONE DEACETYLASE (HDAC) INHIBITOR SODIUM BUTYRATE IN THE HIPPOCAMPUS KINDLING MODEL OF TEMPORAL LOBE EPILEPSY (TLE), A CLASSIC MODEL HEAVILY USED TO APPROVE DRUGS FOR TREATMENT OF EPILEPSY. DAILY TREATMENT WITH BUTYRATE SIGNIFICANTLY INHIBITED HDAC ACTIVITY AND RETARDED THE DEVELOPMENT OF LIMBIC EPILEPTOGENESIS WITHOUT AFFECTING AFTER-DISCHARGE SIGNAL. HDAC INHIBITION MARKEDLY IMPAIRED THE PERSISTENCE OF SEIZURE EXPRESSION MANY WEEKS AFTER EPILEPSY DEVELOPMENT. MOREOVER, SUBCHRONIC HDAC INHIBITION FOR 2 WEEKS RESULTED IN A STRIKING RETARDATION OF EPILEPTOGENESIS. HDAC INHIBITION, UNEXPECTEDLY, ALSO SHOWED ERASURE OF THE EPILEPTOGENIC STATE IN EPILEPTIC ANIMALS. FINALLY, BUTYRATE-TREATED ANIMALS EXHIBITED A POWERFUL REDUCTION IN MOSSY FIBER SPROUTING, A MORPHOLOGIC INDEX OF EPILEPTOGENESIS. TOGETHER THESE RESULTS UNDERSCORE THAT HDAC INHIBITION PREVENTS THE DEVELOPMENT OF TLE, INDICATING HDAC'S CRITICAL SIGNALING ROLE IN EPILEPTOGENESIS. THESE FINDINGS, THEREFORE, ENVISAGE A UNIQUE NOVEL THERAPY FOR PREVENTING OR CURING EPILEPSY BY TARGETING THE EPIGENETIC HDAC PATHWAY. 2018 2 6748 27 WHOLE GENOME METHYLATION ARRAY ANALYSIS REVEALS NEW ASPECTS IN BALKAN ENDEMIC NEPHROPATHY ETIOLOGY. BACKGROUND: BALKAN ENDEMIC NEPHROPATHY (BEN) REPRESENTS A CHRONIC PROGRESSIVE INTERSTITIAL NEPHRITIS IN STRIKING CORRELATION WITH UROEPITHELIAL TUMOURS OF THE UPPER URINARY TRACT. THE DISEASE HAS ENDEMIC DISTRIBUTION IN THE DANUBE RIVER REGIONS IN SEVERAL BALKAN COUNTRIES.DNA METHYLATION IS A PRIMARY EPIGENETIC MODIFICATION THAT IS INVOLVED IN MAJOR PROCESSES SUCH AS CANCER, GENOMIC IMPRINTING, GENE SILENCING, ETC. THE SIGNIFICANCE OF CPG ISLAND METHYLATION STATUS IN NORMAL DEVELOPMENT, CELL DIFFERENTIATION AND GENE EXPRESSION IS WIDELY RECOGNIZED, ALTHOUGH STILL STAYS POORLY UNDERSTOOD. METHODS: WE PERFORMED WHOLE GENOME DNA METHYLATION ARRAY ANALYSIS ON DNA POOL SAMPLES FROM PERIPHERAL BLOOD FROM 159 AFFECTED INDIVIDUALS AND 170 HEALTHY INDIVIDUALS. THIS TECHNIQUE ALLOWED US TO DETERMINE THE METHYLATION STATUS OF 27 627 CPG ISLANDS THROUGHOUT THE WHOLE GENOME IN HEALTHY CONTROLS AND BEN PATIENTS. THUS WE OBTAINED THE METHYLATION PROFILE OF BEN PATIENTS FROM BULGARIAN AND SERBIAN ENDEMIC REGIONS. RESULTS: USING SPECIFICALLY DEVELOPED SOFTWARE WE COMPARED THE METHYLATION PROFILES OF BEN PATIENTS AND CORRESPONDING CONTROLS AND REVEALED THE DIFFERENTLY METHYLATED REGIONS. WE THEN COMPARED THE DMRS BETWEEN ALL PATIENT-CONTROL PAIRS TO DETERMINE COMMON CHANGES IN THE EPIGENETIC PROFILES.SEC61G, IL17RA, HDAC11 PROVED TO BE DIFFERENTLY METHYLATED THROUGHOUT ALL PATIENT-CONTROL PAIRS. THE CPG ISLANDS OF ALL 3 GENES WERE HYPOMETHYLATED COMPARED TO CONTROLS. THIS SUGGESTS THAT DYSREGULATION OF THESE GENES INVOLVED IN IMMUNOLOGICAL RESPONSE COULD BE A COMMON MECHANISM IN BEN PATHOGENESIS IN BOTH ENDEMIC REGIONS AND IN BOTH GENDERS. CONCLUSION: OUR DATA PROPOSE A NEW HYPOTHESIS THAT IMMUNOLOGIC DYSREGULATION HAS A PLACE IN BEN ETIOPATHOGENESIS. 2013 3 5497 45 REVIEW: ANIMAL MODELS OF ACQUIRED EPILEPSY: INSIGHTS INTO MECHANISMS OF HUMAN EPILEPTOGENESIS. IN MANY PATIENTS WHO SUFFER FROM EPILEPSIES, RECURRENT EPILEPTIC SEIZURES DO NOT START AT BIRTH BUT DEVELOP LATER IN LIFE. THIS HOLDS PARTICULARLY TRUE FOR EPILEPSIES WITH A FOCAL SEIZURE ORIGIN INCLUDING FOCAL CORTICAL DYSPLASIAS AND TEMPORAL LOBE EPILEPSY (TLE). TLE MOST FREQUENTLY HAS ITS SEIZURE ONSET IN THE HIPPOCAMPAL FORMATION. HIPPOCAMPAL BIOPSIES OF PHARMACORESISTANT TLE PATIENTS UNDERGOING EPILEPSY SURGERY FOR SEIZURE CONTROL MOST FREQUENTLY REVEAL THE DAMAGE PATTERN OF HIPPOCAMPAL SCLEROSIS, THAT IS, SEGMENTAL NEURONAL CELL LOSS AND CONCOMITANT ASTROGLIOSIS. MANY TLE PATIENTS REPORT ON TRANSIENT BRAIN INSULTS EARLY IN LIFE, WHICH IS FOLLOWED BY A 'LATENCY' PERIOD LACKING SEIZURE ACTIVITY OF MONTHS OR EVEN YEARS BEFORE CHRONIC RECURRENT SEIZURES START. THE PLETHORA OF STRUCTURAL AND CELLULAR MECHANISMS THAT CONVERT THE HIPPOCAMPAL FORMATION TO BECOME CHRONICALLY HYPEREXCITABLE AFTER A TRANSIENT INSULT TO THE BRAIN ARE SUMMARIZED UNDER THE TERM EPILEPTOGENESIS. IN CONTRAST TO THE OBSTACLES ARISING FOR EXPERIMENTAL STUDIES OF EPILEPTOGENESIS ASPECTS IN HUMAN SURGICAL HIPPOCAMPAL TISSUE, RECENT ANIMAL MODEL APPROACHES ALLOW INSIGHTS INTO MECHANISMS OF EPILEPTOGENESIS. RELEVANT MODELS OF TRANSIENT BRAIN INSULTS IN THIS CONTEXT COMPRISE SEVERAL DISTINCT TYPES OF LESIONS INCLUDING EXCITOXIC STATUS EPILEPTICUS (SE), ELECTRICAL SEIZURE INDUCTION, TRAUMATIC BRAIN INJURY, INDUCTION OF INFLAMMATORY PROCESSES BY HYPERTHERMIA AND VIRAL INFLAMMATION AND OTHERS. IN PATHOGENETIC TERMS, ABERRANT TRANSCRIPTIONAL AND EPIGENETIC REPROGRAMMING, ACQUIRED CHANNEL- AND SYNAPTOPATHIES, NEURONAL NETWORK AND BLOOD-BRAIN BARRIER DYSFUNCTION AS WELL AS INNATE AND ADAPTIVE IMMUNITY-MEDIATED DAMAGE PLAY MAJOR ROLES. IN SUBSEQUENT STEPS, RESPECTIVE ANIMAL MODELS HAVE BEEN USED IN ORDER TO TEST WHETHER THIS DYNAMIC PROCESS CAN BE EITHER RETARDED OR EVEN ABOLISHED BY INTERFERING WITH EPILEPTOGENIC MECHANISMS. WELL-CONTROLLED SUBSEQUENT ANALYSES OF EPILEPTOGENIC CASCADES CHARACTERIZED IN ANIMAL MODELS USING CAREFULLY STRATIFIED HUMAN HIPPOCAMPAL BIOPSIES TO EXPLOIT THE UNIQUE OPPORTUNITIES GIVEN BY THESE RARE AND PRECIOUS BRAIN TISSUE SAMPLES AIM TO TRANSLATE INTO NOVEL ANTIEPILEPTOGENIC APPROACHES. RESPECTIVE PRECLINICAL TESTS CAN OPEN ENTIRELY NEW PERSPECTIVES FOR TAILOR-MADE TREATMENTS IN PATIENTS WITH THE POTENTIAL TO AVOID THE EMERGENCE OF CHRONIC FOCAL SEIZURE EVENTS. 2018 4 2654 34 EPILEPSY PROGRESSION IS ASSOCIATED WITH CUMULATIVE DNA METHYLATION CHANGES IN INFLAMMATORY GENES. MESIAL TEMPORAL LOBE EPILEPSY WITH HIPPOCAMPAL SCLEROSIS (MTLE-HS) IS THE MOST COMMON FOCAL EPILEPSY IN ADULTS. IT IS CHARACTERIZED BY ALARMING RATES OF PHARMACORESISTANCE. EPILEPTOGENESIS IS ASSOCIATED WITH THE OCCURRENCE OF EPIGENETIC ALTERATIONS, AND THE FEW EPIGENETIC STUDIES CARRIED OUT IN MTLE-HS HAVE MAINLY FOCUSED ON THE HIPPOCAMPUS. IN THIS STUDY, WE OBTAINED THE DNA METHYLATION PROFILES FROM BOTH THE HIPPOCAMPUS AND ANTERIOR TEMPORAL NEOCORTEX OF MTLE-HS PATIENTS SUBJECTED TO RESECTIVE EPILEPSY SURGERY AND AUTOPSIED NON-EPILEPTIC CONTROLS. WE ASSESSED THE PROGRESSIVE NATURE OF DNA METHYLATION CHANGES IN RELATION TO EPILEPSY DURATION. WE IDENTIFIED SIGNIFICANTLY ALTERED HIPPOCAMPAL DNA METHYLATION PATTERNS ENCOMPASSING MULTIPLE PATHWAYS KNOWN TO BE INVOLVED IN EPILEPTOGENESIS. DNA METHYLATION CHANGES WERE EVEN MORE STRIKING IN THE NEOCORTEX, WHEREIN PATHOGENIC PATHWAYS AND GENES WERE COMMON TO BOTH TISSUES. MOST IMPORTANTLY, DNA METHYLATION CHANGES AT MANY GENOMIC SITES VARIED SIGNIFICANTLY WITH EPILEPSY DURATION. SUCH PROGRESSIVE CHANGES WERE ASSOCIATED WITH INFLAMMATION-RELATED GENES IN THE HIPPOCAMPUS. OUR RESULTS SUGGEST THAT THE NEOCORTEX, RELATIVELY SPARED OF EXTENSIVE HISTOPATHOLOGICAL DAMAGE, MAY ALSO BE INVOLVED IN EPILEPSY DEVELOPMENT. THESE RESULTS ALSO OPEN THE POSSIBILITY THAT THE OBSERVED NEOCORTICAL IMPAIRMENT COULD REPRESENT A PRELIMINARY STAGE OF EPILEPTOGENESIS BEFORE THE ESTABLISHMENT OF CHRONIC LESIONS OR A CONSEQUENCE OF PROLONGED SEIZURE EXPOSURE. OUR TWO-TISSUE MULTI-LEVEL CHARACTERIZATION OF THE MTLE-HS DNA METHYLOME SUGGESTS THE OCCURRENCE OF A SELF-PROPAGATING INFLAMMATORY WAVE OF EPIGENETIC DYSREGULATION. 2022 5 6317 34 THE RELEVANCE OF INTER- AND INTRASTRAIN DIFFERENCES IN MICE AND RATS AND THEIR IMPLICATIONS FOR MODELS OF SEIZURES AND EPILEPSY. IT IS BECOMING INCREASINGLY CLEAR THAT THE GENETIC BACKGROUND OF MICE AND RATS, EVEN IN INBRED STRAINS, CAN HAVE A PROFOUND INFLUENCE ON MEASURES OF SEIZURE SUSCEPTIBILITY AND EPILEPSY. THESE DIFFERENCES CAN BE CAPITALIZED UPON THROUGH GENETIC MAPPING STUDIES TO REVEAL GENES IMPORTANT FOR SEIZURES AND EPILEPSY. HOWEVER, STRAIN BACKGROUND AND PARTICULARLY MIXED GENETIC BACKGROUNDS OF TRANSGENIC ANIMALS NEED CAREFUL CONSIDERATION IN BOTH THE SELECTION OF STRAINS AND IN THE INTERPRETATION OF RESULTS AND CONCLUSIONS. FOR INSTANCE, MICE WITH TARGETED DELETIONS OF GENES INVOLVED IN EPILEPSY CAN HAVE PROFOUNDLY DISPARATE PHENOTYPES DEPENDING ON THE BACKGROUND STRAIN. IN THIS REVIEW, WE DISCUSS FINDINGS RELATED TO HOW THIS GENETIC HETEROGENEITY HAS AND CAN BE UTILIZED IN THE EPILEPSY FIELD TO REVEAL NOVEL INSIGHTS INTO SEIZURES AND EPILEPSY. MOREOVER, WE DISCUSS HOW CAUTION IS NEEDED IN REGARDS TO RODENT STRAIN OR EVEN ANIMAL VENDOR CHOICE, AND HOW THIS CAN SIGNIFICANTLY INFLUENCE SEIZURE AND EPILEPSY PARAMETERS IN UNEXPECTED WAYS. THIS IS PARTICULARLY CRITICAL IN DECISIONS REGARDING THE STRAIN OF CHOICE USED IN GENERATING MICE WITH TARGETED DELETIONS OF GENES. FINALLY, WE DISCUSS THE ROLE OF ENVIRONMENT (AT VENDOR AND/OR LABORATORY) AND EPIGENETIC FACTORS FOR INTER- AND INTRASTRAIN DIFFERENCES AND HOW SUCH DIFFERENCES CAN AFFECT THE EXPRESSION OF SEIZURES AND THE ANIMALS' PERFORMANCE IN BEHAVIORAL TESTS THAT OFTEN ACCOMPANY ACUTE AND CHRONIC SEIZURE TESTING. 2017 6 4921 32 PARENT-OF-ORIGIN EFFECTS IMPLICATE EPIGENETIC REGULATION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS AND IDENTIFY IMPRINTED DLK1 AS A NOVEL RISK GENE. PARENT-OF-ORIGIN EFFECTS COMPRISE A RANGE OF GENETIC AND EPIGENETIC MECHANISMS OF INHERITANCE. RECENTLY, DETECTION OF SUCH EFFECTS IMPLICATED EPIGENETIC MECHANISMS IN THE ETIOLOGY OF MULTIPLE SCLEROSIS (MS), A CHRONIC INFLAMMATORY DISEASE OF THE CENTRAL NERVOUS SYSTEM. WE HERE SOUGHT TO DISSECT THE MAGNITUDE AND THE TYPE OF PARENT-OF-ORIGIN EFFECTS IN THE PATHOGENESIS OF EXPERIMENTAL NEUROINFLAMMATION UNDER CONTROLLED ENVIRONMENTAL CONDITIONS. WE INVESTIGATED INHERITANCE OF AN MS-LIKE DISEASE IN RAT, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE), USING A BACKCROSS STRATEGY DESIGNED TO IDENTIFY THE PARENTAL ORIGIN OF DISEASE-PREDISPOSING ALLELES. A STRIKING 37-54% OF ALL DETECTED DISEASE-PREDISPOSING LOCI DEPENDED ON PARENTAL TRANSMISSION. ADDITIONALLY, THE Y CHROMOSOME FROM THE SUSCEPTIBLE STRAIN CONTRIBUTED TO DISEASE SUSCEPTIBILITY. ACCOUNTING FOR PARENT-OF-ORIGIN ENABLED MORE POWERFUL AND PRECISE IDENTIFICATION OF NOVEL RISK FACTORS AND INCREASED THE DISEASE VARIANCE EXPLAINED BY THE IDENTIFIED FACTORS BY 2-4-FOLD. THE MAJORITY OF LOCI DISPLAYED AN IMPRINTING-LIKE PATTERN WHEREBY A GENE EXPRESSED ONLY FROM THE MATERNAL OR PATERNAL COPY EXERTS AN EFFECT. IN PARTICULAR, A LOCUS ON CHROMOSOME 6 COMPRISES A WELL-KNOWN CLUSTER OF IMPRINTED GENES INCLUDING THE PATERNALLY EXPRESSED DLK1, AN ATYPICAL NOTCH LIGAND. DISEASE-PREDISPOSING ALLELES AT THE LOCUS CONFERRED LOWER DLK1 EXPRESSION IN RATS AND, TOGETHER WITH DATA FROM TRANSGENIC OVEREXPRESSING DLK1 MICE, DEMONSTRATE THAT REDUCED DLK1 DRIVES MORE SEVERE DISEASE AND MODULATES ADAPTIVE IMMUNE REACTIONS IN EAE. OUR FINDINGS SUGGEST A SIGNIFICANT EPIGENETIC CONTRIBUTION TO THE ETIOLOGY OF EAE. INCORPORATING THESE EFFECTS ENABLES MORE POWERFUL AND PRECISE IDENTIFICATION OF NOVEL RISK FACTORS WITH DIAGNOSTIC AND PROGNOSTIC IMPLICATIONS FOR COMPLEX DISEASE. 2014 7 2251 25 EPIGENETIC MODULATION OF VASOPRESSIN EXPRESSION IN HEALTH AND DISEASE. VASOPRESSIN IS A UBIQUITOUS MOLECULE PLAYING AN IMPORTANT ROLE IN A WIDE RANGE OF PHYSIOLOGICAL PROCESSES THEREBY IMPLICATED IN THE PATHOMECHANISM OF MANY DISORDERS. ITS EFFECT IS WELL CHARACTERIZED THROUGH V2 RECEPTORS, WHICH REGULATES THE WATER RESORPTION IN KIDNEY, WHILE ITS VASOCONSTRICTORY EFFECT THROUGH V1A RECEPTOR ALSO RECEIVED A LOT OF ATTENTION IN THE MAINTENANCE OF BLOOD PRESSURE DURING SHOCK. HOWEVER, THE MOST STRIKING IS ITS CENTRAL EFFECT BOTH THROUGH THE V1B RECEPTORS IN STRESS-AXIS REGULATION AS WELL AS THROUGH V1A RECEPTORS REGULATING MANY ASPECTS OF OUR BEHAVIOR (E.G., SOCIAL BEHAVIOR, LEARNING AND MEMORY). VASOPRESSIN HAS BEEN IMPLICATED IN THE DEVELOPMENT OF DEPRESSION, DUE TO ITS CONNECTION WITH CHRONIC STRESS, AS WELL AS SCHIZOPHRENIA BECAUSE OF ITS INVOLVEMENT IN SOCIAL INTERACTIONS AND MEMORY PROCESSES. EPIGENETIC CHANGES MAY ALSO PLAY A ROLE IN THE DEVELOPMENT OF THESE DISORDERS. THE POSSIBLE MECHANISM INCLUDES DNA METHYLATION, HISTONE MODIFICATION AND/OR MICRO RNAS, AND THESE POSSIBLE REGULATIONS WILL BE IN THE FOCUS OF OUR PRESENT REVIEW. 2021 8 1442 36 DIFFERENTIAL RESPONSE OF HUMAN HEPATOCYTE CHROMATIN TO HDAC INHIBITORS AS A FUNCTION OF MICROENVIRONMENTAL GLUCOSE LEVEL. DIABETES IS A COMPLEX MULTIFACTORIAL DISORDER CHARACTERIZED BY CHRONIC HYPERGLYCEMIA DUE TO IMPAIRED INSULIN SECRETION. RECENT OBSERVATIONS SUGGEST THAT THE COMPLEXITY OF THE DISEASE CANNOT BE ENTIRELY ACCOUNTED FOR GENETIC PREDISPOSITION AND A COMPELLING ARGUMENT FOR AN EPIGENETIC COMPONENT IS RAPIDLY EMERGING. THE USE OF HISTONE DEACETYLASE INHIBITOR (HDACI) IN CLINICAL SETTING IS AN EMERGING AREA OF INVESTIGATION. IN THIS STUDY, WE HAVE AIMED TO UNDERSTAND AND COMPARE THE RESPONSE OF HEPATOCYTE CHROMATIN TO VALPROIC ACID (VPA) AND TRICHOSTATIN A (TSA) TREATMENTS UNDER NORMOGLYCEMIC OR HYPERGLYCEMIC CONDITIONS TO EXPAND OUR KNOWLEDGE ABOUT THE CONSEQUENCES OF HDACI TREATMENT IN A DIABETES CELL MODEL. UNDER NORMOGLYCEMIC CONDITIONS, THESE TREATMENTS PROMOTED CHROMATIN REMODELING, AS ASSESSED BY IMAGE ANALYSIS AND H3K9AC AND H3K9ME2 ABUNDANCE. SIMULTANEOUSLY, H3K9AC MARKS SHIFTED TO THE NUCLEAR PERIPHERY ACCOMPANIED BY HP1 DISSOCIATION FROM THE HETEROCHROMATIN AND A G1 CELL CYCLE ARREST. MORE STRIKING CHANGES IN THE CELL CYCLE PROGRESSION AND MITOTIC RATIOS REQUIRED DRASTIC TREATMENT. UNDER HYPERGLYCEMIC CONDITIONS, HIGH GLUCOSE PER SE PROMOTED CHROMATIN CHANGES SIMILAR TO THOSE PROMOTED BY VPA AND TSA. NONETHELESS, THESE RESULTS WERE NOT INTENSIFIED IN CELLS TREATED WITH HDACIS UNDER HYPERGLYCEMIC CONDITIONS. DESPITE THE ABSENCE OF MORPHOLOGICAL CHANGES BEING PROMOTED, HDACI TREATMENT SEEMS TO CONFER A PHYSIOLOGICAL MEANING, AMELIORATING THE CELLULAR HYPERGLYCEMIC STATE THROUGH REDUCTION OF GLUCOSE PRODUCTION. THESE OBSERVATIONS ALLOW US TO CONCLUDE THAT THE GLUCOSE LEVEL TO WHICH THE HEPATOCYTES ARE SUBJECTED AFFECTS HOW CHROMATIN RESPONDS TO HDACI AND THEIR ACTION UNDER HIGH-GLUCOSE ENVIRONMENT MIGHT NOT REFLECT ON CHROMATIN REMODELING. J. CELL. PHYSIOL. 231: 2257-2265, 2016. (C) 2016 WILEY PERIODICALS, INC. 2016 9 2871 29 FUNCTIONAL GENOMICS IN EXPERIMENTAL AND HUMAN TEMPORAL LOBE EPILEPSY: POWERFUL NEW TOOLS TO IDENTIFY MOLECULAR DISEASE MECHANISMS OF HIPPOCAMPAL DAMAGE. THE HUMAN GENOME PROJECT IS A MILESTONE FOR MOLECULAR GENETIC STUDIES ON COMPLEX, SPORADIC DISORDERS IN THE HUMAN CENTRAL NERVOUS SYSTEM (CNS). FUNCTIONAL ANALYSIS AND TISSUE-/CELL-SPECIFIC EXPRESSION PROFILES WILL BE OF PARTICULAR IMPORTANCE ANTICIPATING THE MAGNITUDE OF EXPRESSED GENES IN THE BRAIN AND THEIR DYNAMIC EPIGENETIC MODIFICATIONS. THE RECENT PROGRESS IN MICROARRAY TECHNOLOGIES ALLOWS EXPRESSION STUDIES FOR A LARGE NUMBER OF GENES. IN COMBINATION WITH LASER-MICRODISSECTION AND QUANTITATIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION TECHNOLOGIES, SUCH LARGE-SCALE EXPRESSION ANALYSES CAN BE SUCCESSFULLY ADDRESSED IN WELL-DEFINED TISSUE SPECIMENS OR CELLULAR SUBPOPULATIONS. COMPLEX, SPORADIC DISEASES, SUCH AS TEMPORAL LOBE EPILEPSY (TLE), ARE CHALLENGING FOR FUNCTIONAL GENOMICS. ISSUES OF PARTICULAR IMPORTANCE IN THIS FIELD INCLUDE MOLECULAR MECHANISMS OF NEURODEVELOPMENTAL ABNORMALITIES, NEURONAL PLASTICITY AND HYPEREXCITABILITY AS WELL AS NEURONAL CELL DAMAGE IN AFFECTED CNS AREAS. THE AVAILABILITY OF ANATOMICALLY WELL-PRESERVED SURGICAL SPECIMENS, I.E. HIPPOCAMPUS OBTAINED FROM EPILEPSY PATIENTS WITH AMMON'S HORN SCLEROSIS OR FOCAL LESIONS NOT AFFECTING THE HIPPOCAMPUS PROPER AS WELL AS COMPARISONS WITH EXPERIMENTAL TLE MODELS MAY HELP TO ELUCIDATE SPECIFIC MOLECULAR-PATHOLOGICAL MECHANISMS DURING EPILEPTOGENESIS AND IN CHRONIC CONDITIONS OF THE DISEASE. 2002 10 4355 33 MIR-30 FAMILY MIRNAS MEDIATE THE EFFECT OF CHRONIC SOCIAL DEFEAT STRESS ON HIPPOCAMPAL NEUROGENESIS IN MOUSE DEPRESSION MODEL. DEPRESSION IS A DEBILITATING PSYCHIATRIC DISORDER WITH A HIGH RATE OF RELAPSE AND A LOW RATE OF RESPONSE TO ANTIDEPRESSANT TREATMENT. THERE IS A DEARTH OF NEW ANTIDEPRESSANTS DUE TO AN INCOMPLETE UNDERSTANDING OF THE MOLECULAR MECHANISMS INVOLVED IN ITS ETIOPATHOLOGY. CHRONIC STRESS APPEARS TO BE ONE OF THE FOREMOST UNDERLYING CAUSES OF DEPRESSION. STUDIES IN ANIMAL MODELS IN THE PAST DECADE HAVE IMPLICATED EPIGENETIC MECHANISMS IN MEDIATING THE NEGATIVE EFFECTS OF CHRONIC STRESSFUL EVENTS ON THE PROGRESSION/MANIFESTATION OF DEPRESSION AND OTHER CO-MORBID NEUROPSYCHIATRIC DISORDERS. HOWEVER, NON-CODING RNAS, ANOTHER LAYER OF EPIGENETIC REGULATION IS RELATIVELY LESS STUDIED IN DEPRESSION. HERE, USING THE CHRONIC SOCIAL DEFEAT STRESS (CSDS)-INDUCED DEPRESSION MODEL, WE HYPOTHESIZED DYSREGULATION IN MIRNA-MRNA NETWORKS IN THE NEUROGENIC DENTATE GYRUS (DG) REGION OF MALE C57BL/6 MICE. AMONG SEVERAL DYSREGULATED MIRNAS IDENTIFIED VIA MIRNA ARRAYS, THE MOST STRIKING FINDING WAS THE DOWNREGULATION OF MIRNAS OF THE MIR-30 FAMILY IN STRESSED/DEFEATED MICE. TO INVESTIGATE MIRNAS IN THE DG-RESIDENT NEURAL STEM/PROGENITOR CELLS (NSCS/NPCS), WE USED THE IN VITRO NEUROSPHERE CULTURE, WHERE PROLIFERATING NSCS/NPCS WERE SUBJECTED TO DIFFERENTIATION. AMONG SEVERAL DIFFERENTIALLY EXPRESSED MIRNAS, WE OBSERVED AN UPREGULATION OF MIR-30 FAMILY MIRNAS UPON DIFFERENTIATION. TO SEARCH FOR THE GENE TARGETS OF THESE MIRNAS, WE PERFORMED GENE ARRAYS FOLLOWED BY BIOINFORMATICS ANALYSIS, MIRNA MANIPULATIONS AND LUCIFERASE ASSAYS. OUR RESULTS SUGGEST THAT MIR-30 FAMILY MIRNAS MEDIATE CHRONIC STRESS-INDUCED DEPRESSION-LIKE PHENOTYPE BY ALTERING HIPPOCAMPAL NEUROGENESIS AND NEUROPLASTICITY VIA CONTROLLING THE EPIGENETIC AND TRANSCRIPTION REGULATORS SUCH AS MLL3 AND RUNX1; AND CELL SIGNALING REGULATORS LIKE SOCS3, PPP3R1, GPR125, AND NRP1. 2019 11 5146 34 POTENTIAL ROLES FOR INFECTIOUS AGENTS IN THE PATHOPHYSIOLOGY OF PRIMARY BILIARY CIRRHOSIS: WHAT'S NEW? PRIMARY BILIARY CIRRHOSIS (PBC) IS A PROGRESSIVE CHOLESTATIC LIVER DISEASE SEROLOGICALLY CHARACTERIZED BY THE PRESENCE OF HIGH-TITER ANTIMITOCHONDRIAL ANTIBODIES AND, HISTOLOGICALLY BY CHRONIC NONSUPPURATIVE CHOLANGITIS AND GRANULOMATA. THE AETIOLOGY OF THE DISEASE REMAINS ELUSIVE, ALTHOUGH GENETIC, EPIGENETIC, ENVIRONMENTAL, AND INFECTIOUS FACTORS HAVE BEEN CONSIDERED IMPORTANT FOR THE INDUCTION OF THE DISEASE IN GENETICALLY PRONE INDIVIDUALS. THE DISEASE SHOWS A STRIKING FEMALE PREDOMINANCE AND BECOMES CLINICALLY OVERT AT THE FOURTH TO SIXTH DECADE. THESE CHARACTERISTICS HAVE PROMPTED INVESTIGATORS TO CONSIDER INFECTIONS THAT PREDOMINATE IN WOMEN AT THESE AGES AS THE LIKELY CANDIDATES FOR TRIGGERING THE DISEASE. RECURRENT URINARY TRACT INFECTIONS DUE TO ESCHERICHIA COLI WERE THE FIRST INFECTIONS TO BE CONSIDERED PATHOGENETICALLY RELEVANT. OVER THE YEARS, SEVERAL OTHER MICROORGANISMS HAVE BEEN LINKED TO THE PATHOGENESIS OF PBC OWING TO EPIDEMIOLOGICAL, IMMUNOLOGICAL, MICROBIOLOGICAL, OR EXPERIMENTAL FINDINGS IN ANIMAL MODELS. RECENT STUDIES HAVE PROVIDED DATA SUPPORTING THE PATHOGENIC ROLE OF NOVOSPHINGOBIUM AROMATICIVORANS AND BETARETROVIRUSES. SEVERAL REPORTS HAVE LINKED OTHER ORGANISMS TO THE INDUCTION OF THE DISEASE AND/OR THE MAINTENANCE OF THE AUTO-AGGRESSIVE RESPONSES THAT ARE PERPETUATED OVER THE COURSE OF THE DISEASE. THIS REVIEW HIGHLIGHTS THE FINDINGS OF THE MOST RECENT STUDIES INVESTIGATING THE LINK BETWEEN INFECTIONS AND PBC. WE ALSO DISCUSS THE CLOSE INTERPLAY OF THE INFECTIOUS AGENTS WITH OTHER ENVIRONMENTAL AND GENETIC FACTORS, WHICH MAY EXPLAIN THE MULTIFACETED NATURE OF THIS PUZZLING DISEASE. 2013 12 1301 31 DEEP SEQUENCING REVEALS INCREASED DNA METHYLATION IN CHRONIC RAT EPILEPSY. EPILEPSY IS A FREQUENT NEUROLOGICAL DISORDER, ALTHOUGH ONSET AND PROGRESSION OF SEIZURES REMAIN DIFFICULT TO PREDICT IN AFFECTED PATIENTS, IRRESPECTIVE OF THEIR EPILEPTOGENIC CONDITION. PREVIOUS STUDIES IN ANIMAL MODELS AS WELL AS HUMAN EPILEPTIC BRAIN TISSUE REVEALED A REMARKABLY DIVERSE PATTERN OF GENE EXPRESSION IMPLICATING EPIGENETIC CHANGES TO CONTRIBUTE TO DISEASE PROGRESSION. HERE WE MAPPED FOR THE FIRST TIME GLOBAL DNA METHYLATION PATTERNS IN CHRONIC EPILEPTIC RATS AND CONTROLS. USING METHYL-CPG CAPTURE ASSOCIATED WITH MASSIVE PARALLEL SEQUENCING (METHYL-SEQ) WE REPORT THE GENOMIC METHYLATION SIGNATURE OF THE CHRONIC EPILEPTIC STATE. WE OBSERVED A PREDOMINANT INCREASE, RATHER THAN LOSS OF DNA METHYLATION IN CHRONIC RAT EPILEPSY. ABERRANT METHYLATION PATTERNS WERE INVERSELY CORRELATED WITH GENE EXPRESSION CHANGES USING MRNA SEQUENCING FROM SAME ANIMALS AND TISSUE SPECIMENS. ADMINISTRATION OF A KETOGENIC, HIGH-FAT, LOW-CARBOHYDRATE DIET ATTENUATED SEIZURE PROGRESSION AND AMELIORATED DNA METHYLATION MEDIATED CHANGES IN GENE EXPRESSION. THIS IS THE FIRST REPORT OF UNSUPERVISED CLUSTERING OF AN EPIGENETIC MARK BEING USED IN EPILEPSY RESEARCH TO SEPARATE EPILEPTIC FROM NON-EPILEPTIC ANIMALS AS WELL AS FROM ANIMALS RECEIVING ANTI-CONVULSIVE DIETARY TREATMENT. WE FURTHER DISCUSS THE POTENTIAL IMPACT OF EPIGENETIC CHANGES AS A PATHOGENIC MECHANISM OF EPILEPTOGENESIS. 2013 13 2755 39 EXPRESSION OF CLASS II HISTONE DEACETYLASES IN TWO MOUSE MODELS OF TEMPORAL LOBE EPILEPSY. EPIGENETIC MECHANISMS LIKE ALTERED HISTONE ACETYLATION MAY HAVE A CRUCIAL ROLE IN EPILEPTOGENESIS. IN TWO MOUSE MODELS OF TEMPORAL LOBE EPILEPSY, WE INVESTIGATED CHANGES IN THE EXPRESSION OF CLASS II HISTONE DEACETYLASES (HDAC), A GROUP OF SIGNAL TRANSDUCERS THAT SHUTTLE BETWEEN NUCLEUS AND CYTOPLASM. INTRAHIPPOCAMPAL INJECTION OF KAINIC ACID (KA) INDUCED A STATUS EPILEPTICUS, DEVELOPMENT OF SPONTANEOUS SEIZURES (AFTER 3 DAYS), AND FINALLY CHRONIC EPILEPSY AND GRANULE CELL DISPERSION. EXPRESSION OF CLASS II HDAC MRNAS WAS INVESTIGATED AT DIFFERENT TIME INTERVALS AFTER KA INJECTION IN THE GRANULE CELL LAYERS AND IN SECTORS CA1 AND CA3 CONTRALATERAL TO THE SITE OF KA INJECTION LACKING NEURODEGENERATION. INCREASED EXPRESSION OF HDAC5 AND 9 MRNAS COINCIDED WITH PRONOUNCED GRANULE CELL DISPERSION IN THE KA-INJECTED HIPPOCAMPUS AT LATE INTERVALS (14-28 DAYS AFTER KA) AND EQUALLY AFFECTED BOTH HDAC9 SPLICE VARIANTS. IN CONTRAST, IN THE PILOCARPINE MODEL (SHOWING NO GRANULE CELL DISPERSION), WE OBSERVED DECREASES IN THE EXPRESSION OF HDAC5 AND 9 AT THE SAME TIME INTERVALS. BEYOND THIS, STRIKING SIMILARITIES BETWEEN BOTH TEMPORAL LOBE EPILEPSY MODELS SUCH AS FAST DECREASES IN HDAC7 AND 10 MRNAS DURING THE ACUTE STATUS EPILEPTICUS WERE OBSERVED, NOTABLY ALSO IN THE CONTRALATERAL HIPPOCAMPUS NOT AFFECTED BY NEURODEGENERATION. THE PARTICULAR PATTERNS OF HDAC MRNA EXPRESSION SUGGEST A ROLE IN EPILEPTOGENESIS AND GRANULE CELL DISPERSION. REDUCED EXPRESSION OF HDACS MAY RESULT IN INCREASED EXPRESSION OF PRO- AND ANTICONVULSIVE PROTEINS. ON THE OTHER HAND, EXPORT OF HDACS FROM THE NUCLEUS INTO THE CYTOPLASM COULD ALLOW FOR DEACETYLATION OF CYTOPLASMATIC PROTEINS INVOLVED IN AXONAL AND DENDRITIC REMODELING, LIKE GRANULE CELL DISPERSION. HDAC 5 AND HDAC 9 EXPRESSION IS HIGHLY INCREASED IN GRANULE CELLS OF THE KA-INJECTED HIPPOCAMPUS AND PARALLELS GRANULE CELL DISPERSION. BOTH HDACS ARE THOUGHT TO BE TARGETED TO THE CYTOPLASM AND TO ACT THERE BY DEACETYLATING CYTOPLASMATIC (E.G. CYTOSCELETON-RELATED) PROTEINS. 2016 14 6024 34 THE BIOCHEMISTRY AND EPIGENETICS OF EPILEPSY: FOCUS ON ADENOSINE AND GLYCINE. EPILEPSY, ONE OF THE MOST PREVALENT NEUROLOGICAL CONDITIONS, PRESENTS AS A COMPLEX DISORDER OF NETWORK HOMEOSTASIS CHARACTERIZED BY SPONTANEOUS NON-PROVOKED SEIZURES AND ASSOCIATED COMORBIDITIES. CURRENTLY USED ANTIEPILEPTIC DRUGS HAVE BEEN DESIGNED TO SUPPRESS NEURONAL HYPEREXCITABILITY AND THEREBY TO SUPPRESS EPILEPTIC SEIZURES. HOWEVER, THE CURRENT ARMAMENTARIUM OF ANTIEPILEPTIC DRUGS IS NOT EFFECTIVE IN OVER 30% OF PATIENTS, DOES NOT AFFECT THE COMORBIDITIES OF EPILEPSY, AND DOES NOT PREVENT THE DEVELOPMENT AND PROGRESSION OF EPILEPSY (EPILEPTOGENESIS). PREVENTION OF EPILEPSY AND ITS PROGRESSION REMAINS THE HOLY GRAIL FOR EPILEPSY RESEARCH AND THERAPY DEVELOPMENT, REQUIRING NOVEL CONCEPTUAL ADVANCES TO FIND A SOLUTION TO THIS URGENT MEDICAL NEED. THE METHYLATION HYPOTHESIS OF EPILEPTOGENESIS SUGGESTS THAT CHANGES IN DNA METHYLATION ARE IMPLICATED IN THE PROGRESSION OF THE DISEASE. IN PARTICULAR, GLOBAL DNA HYPERMETHYLATION APPEARS TO BE ASSOCIATED WITH CHRONIC EPILEPSY. CLINICAL AS WELL AS EXPERIMENTAL EVIDENCE DEMONSTRATES THAT EPILEPSY AND ITS PROGRESSION CAN BE PREVENTED BY BIOCHEMICAL MANIPULATIONS AND THOSE THAT TARGET PREVIOUSLY UNRECOGNIZED EPIGENETIC FUNCTIONS CONTRIBUTING TO EPILEPSY DEVELOPMENT AND MAINTENANCE OF THE EPILEPTIC STATE. THIS MINI-REVIEW WILL DISCUSS, EPIGENETIC MECHANISMS IMPLICATED IN EPILEPTOGENESIS AND BIOCHEMICAL INTERACTIONS BETWEEN ADENOSINE AND GLYCINE AS A CONCEPTUAL ADVANCE TO UNDERSTAND THE CONTRIBUTION OF MALADAPTIVE CHANGES IN BIOCHEMISTRY AS A MAJOR CONTRIBUTING FACTOR TO THE DEVELOPMENT OF EPILEPSY. NEW FINDINGS BASED ON BIOCHEMICAL MANIPULATION OF THE DNA METHYLOME SUGGEST THAT: (I) EPIGENETIC MECHANISMS PLAY A FUNCTIONAL ROLE IN EPILEPTOGENESIS; AND (II) THERAPEUTIC RECONSTRUCTION OF THE EPIGENOME IS AN EFFECTIVE ANTIEPILEPTOGENIC THERAPY. 2016 15 124 38 A SYSTEMS APPROACH DELIVERS A FUNCTIONAL MICRORNA CATALOG AND EXPANDED TARGETS FOR SEIZURE SUPPRESSION IN TEMPORAL LOBE EPILEPSY. TEMPORAL LOBE EPILEPSY IS THE MOST COMMON DRUG-RESISTANT FORM OF EPILEPSY IN ADULTS. THE REORGANIZATION OF NEURAL NETWORKS AND THE GENE EXPRESSION LANDSCAPE UNDERLYING PATHOPHYSIOLOGIC NETWORK BEHAVIOR IN BRAIN STRUCTURES SUCH AS THE HIPPOCAMPUS HAS BEEN SUGGESTED TO BE CONTROLLED, IN PART, BY MICRORNAS. TO SYSTEMATICALLY ASSESS THEIR SIGNIFICANCE, WE SEQUENCED ARGONAUTE-LOADED MICRORNAS TO DEFINE FUNCTIONALLY ENGAGED MICRORNAS IN THE HIPPOCAMPUS OF THREE DIFFERENT ANIMAL MODELS IN TWO SPECIES AND AT SIX TIME POINTS BETWEEN THE INITIAL PRECIPITATING INSULT THROUGH TO THE ESTABLISHMENT OF CHRONIC EPILEPSY. WE THEN SELECTED COMMONLY UP-REGULATED MICRORNAS FOR A FUNCTIONAL IN VIVO THERAPEUTIC SCREEN USING OLIGONUCLEOTIDE INHIBITORS. ARGONAUTE SEQUENCING GENERATED 1.44 BILLION SMALL RNA READS OF WHICH UP TO 82% WERE MICRORNAS, WITH OVER 400 UNIQUE MICRORNAS DETECTED PER MODEL. APPROXIMATELY HALF OF THE DETECTED MICRORNAS WERE DYSREGULATED IN EACH EPILEPSY MODEL. WE PRIORITIZED COMMONLY UP-REGULATED MICRORNAS THAT WERE FULLY CONSERVED IN HUMANS AND DESIGNED CUSTOM ANTISENSE OLIGONUCLEOTIDES FOR THESE CANDIDATE TARGETS. ANTISEIZURE PHENOTYPES WERE OBSERVED UPON KNOCKDOWN OF MIR-10A-5P, MIR-21A-5P, AND MIR-142A-5P AND ELECTROPHYSIOLOGICAL ANALYSES INDICATED BROAD SAFETY OF THIS APPROACH. COMBINED INHIBITION OF THESE THREE MICRORNAS REDUCED SPONTANEOUS SEIZURES IN EPILEPTIC MICE. PROTEOMIC DATA, RNA SEQUENCING, AND PATHWAY ANALYSIS ON PREDICTED AND VALIDATED TARGETS OF THESE MICRORNAS IMPLICATED DEREPRESSED TGF-BETA SIGNALING AS A SHARED SEIZURE-MODIFYING MECHANISM. CORRESPONDINGLY, INHIBITION OF TGF-BETA SIGNALING OCCLUDED THE ANTISEIZURE EFFECTS OF THE ANTAGOMIRS. TOGETHER, THESE RESULTS IDENTIFY SHARED, DYSREGULATED, AND FUNCTIONALLY ACTIVE MICRORNAS DURING THE PATHOGENESIS OF EPILEPSY WHICH REPRESENT THERAPEUTIC ANTISEIZURE TARGETS. 2020 16 2141 45 EPIGENETIC INTERVENTIONS FOR EPILEPTOGENESIS: A NEW FRONTIER FOR CURING EPILEPSY. THIS ARTICLE HIGHLIGHTS THE EMERGING THERAPEUTIC POTENTIAL OF SPECIFIC EPIGENETIC MODULATORS AS PROMISING ANTIEPILEPTOGENIC OR DISEASE-MODIFYING AGENTS FOR CURING EPILEPSY. CURRENTLY, THERE IS AN UNMET NEED FOR ANTIEPILEPTOGENIC AGENTS THAT TRULY PREVENT THE DEVELOPMENT OF EPILEPSY IN PEOPLE AT RISK. THERE IS STRONG EVIDENCE THAT EPIGENETIC SIGNALING, WHICH EXERTS HIGH FIDELITY REGULATION OF GENE EXPRESSION, PLAYS A CRUCIAL ROLE IN THE PATHOPHYSIOLOGY OF EPILEPTOGENESIS AND CHRONIC EPILEPSY. THESE MODIFICATIONS ARE NOT HARD-WIRED INTO THE GENOME AND ARE CONSTANTLY REPROGRAMMED BY ENVIRONMENTAL INFLUENCES. THE POTENTIAL EPIGENETIC MECHANISMS, INCLUDING HISTONE MODIFICATIONS, DNA METHYLATION, MICRORNA-BASED TRANSCRIPTIONAL CONTROL, AND BROMODOMAIN READING ACTIVITY, CAN DRASTICALLY ALTER THE NEURONAL GENE EXPRESSION PROFILE BY EXERTING THEIR SUMMATIVE EFFECTS IN A COORDINATED FASHION. SUCH AN EPIGENETIC INTERVENTION APPEARS MORE RATIONAL STRATEGY FOR PREVENTING EPILEPSY BECAUSE IT TARGETS THE PRIMARY PATHWAY THAT INITIALLY TRIGGERS THE NUMEROUS DOWNSTREAM CELLULAR AND MOLECULAR EVENTS MEDIATING EPILEPTOGENESIS. AMONG CURRENTLY APPROVED EPIGENETIC DRUGS, THE MAJORITY ARE ANTICANCER DRUGS WITH WELL-ESTABLISHED PROFILES IN CLINICAL TRIALS AND PRACTICE. EVIDENCE FROM PRECLINICAL STUDIES SUPPORTS THE PREMISE THAT THESE DRUGS MAY BE APPLIED TO A WIDE RANGE OF BRAIN DISORDERS. TARGETING HISTONE DEACETYLATION BY INHIBITING HISTONE DEACETYLASE ENZYMES APPEARS TO BE ONE PROMISING EPIGENETIC THERAPY SINCE CERTAIN INHIBITORS HAVE BEEN SHOWN TO PREVENT EPILEPTOGENESIS IN ANIMAL MODELS. HOWEVER, DEVELOPING NEURONAL SPECIFIC EPIGENETIC MODULATORS REQUIRES RATIONAL, PATHOPHYSIOLOGY-BASED OPTIMIZATION TO EFFICIENTLY INTERCEPT THE UPSTREAM PATHWAYS IN EPILEPTOGENESIS. OVERALL, EPIGENETIC AGENTS HAVE BEEN WELL POSITIONED AS NEW FRONTIER TOOLS TOWARDS THE NATIONAL GOAL OF CURING EPILEPSY. 2017 17 5506 28 RHEUMATOID ARTHRITIS AND PRIMARY BILIARY CIRRHOSIS: CAUSE, CONSEQUENCE, OR COINCIDENCE? PRIMARY BILIARY CIRRHOSIS (PBC) IS A PROGRESSIVE CHOLESTATIC LIVER DISEASE CHARACTERIZED SEROLOGICALLY BY CHOLESTASIS AND THE PRESENCE OF HIGH-TITRE ANTIMITOCHONDRIAL ANTIBODIES AND HISTOLOGICALLY BY CHRONIC NONSUPPURATIVE CHOLANGITIS AND GRANULOMATA. PBC PATIENTS OFTEN HAVE CONCOMITANT AUTOIMMUNE DISEASES, INCLUDING ARTHROPATHIES. THIS RAISES THE QUESTION AS TO WHETHER THERE ARE SHARED FEATURES IN THE PATHOGENESIS OF THOSE DISEASES WITH THE PATHOGENESIS OF PBC. EPIDEMIOLOGICAL AND LARGE CASE STUDIES HAVE INDICATED THAT ALTHOUGH THE INCIDENCE OF RHEUMATOID ARTHRITIS (RA) IS NOT SIGNIFICANTLY RAISED IN PBC PATIENTS, THERE APPEARS TO BE A HIGHER RATE OF RA IN PBC PATIENTS AND THEIR RELATIVES. GENETIC STUDIES HAVE DEMONSTRATED THAT SEVERAL GENES IMPLICATED IN PBC HAVE ALSO BEEN IMPLICATED IN RA. EPIGENETIC STUDIES PROVIDED A WEALTH OF DATA REGARDING RA, BUT THE FINDINGS ON EPIGENETIC CHANGES IN PBC ARE VERY LIMITED. AS WELL, CERTAIN INFECTIOUS AGENTS IDENTIFIED IN THE PATHOGENESIS OF PBC MAY ALSO PLAY A ROLE IN THE PATHOGENESIS OF RA. THESE DATA SUGGEST THAT ALTHOUGH RA IS NOT SIGNIFICANTLY PRESENT IN PBC, SOME INDIVIDUALS WITH CERTAIN GENETIC TRAITS AND ENVIRONMENTAL EXPOSURES MAY DEVELOP BOTH CONDITIONS. THIS CONCEPT MAY ALSO APPLY TO OTHER CONCOMITANT DISEASES FOUND IN PBC PATIENTS. 2012 18 2264 25 EPIGENETIC PROGRAMMING BY STRESS AND GLUCOCORTICOIDS ALONG THE HUMAN LIFESPAN. PSYCHOSOCIAL STRESS TRIGGERS A SET OF BEHAVIORAL, NEURAL, HORMONAL, AND MOLECULAR RESPONSES THAT CAN BE A DRIVING FORCE FOR SURVIVAL WHEN ADAPTIVE AND TIME-LIMITED, BUT MAY ALSO CONTRIBUTE TO A HOST OF DISEASE STATES IF DYSREGULATED OR CHRONIC. THE BENEFICIAL OR DETRIMENTAL EFFECTS OF STRESS ARE LARGELY MEDIATED BY THE HYPOTHALAMIC-PITUITARY AXIS, A HIGHLY CONSERVED NEUROHORMONAL CASCADE THAT CULMINATES IN SYSTEMIC SECRETION OF GLUCOCORTICOIDS. GLUCOCORTICOIDS ACTIVATE THE GLUCOCORTICOID RECEPTOR, A UBIQUITOUS NUCLEAR RECEPTOR THAT NOT ONLY CAUSES WIDESPREAD CHANGES IN TRANSCRIPTIONAL PROGRAMS, BUT ALSO INDUCES LASTING EPIGENETIC MODIFICATIONS IN MANY TARGET TISSUES. WHILE THE EPIGENOME REMAINS SENSITIVE TO STRESSORS THROUGHOUT LIFE, WE PROPOSE TWO KEY PRINCIPLES THAT MAY GOVERN THE EPIGENETICS OF STRESS AND GLUCOCORTICOIDS ALONG THE LIFESPAN: FIRST, THE PRESENCE OF DISTINCT LIFE PERIODS, DURING WHICH THE EPIGENOME SHOWS HEIGHTENED PLASTICITY TO STRESS EXPOSURE, SUCH AS IN EARLY DEVELOPMENT AND AT ADVANCED AGE; AND, SECOND, THE POTENTIAL OF STRESS-INDUCED EPIGENETIC CHANGES TO ACCUMULATE THROUGHOUT LIFE BOTH IN SELECT CHROMATIN REGIONS AND AT THE GENOME-WIDE LEVEL. THESE PRINCIPLES HAVE IMPORTANT CLINICAL AND TRANSLATIONAL IMPLICATIONS, AND THEY SHOW STRIKING PARALLELS WITH THE EXISTENCE OF SENSITIVE DEVELOPMENTAL PERIODS AND THE CUMULATIVE IMPACT OF STRESSFUL EXPERIENCES ON THE DEVELOPMENT OF STRESS-RELATED PHENOTYPES. WE HOPE THAT THIS CONCEPTUAL MECHANISTIC FRAMEWORK WILL STIMULATE FRUITFUL RESEARCH THAT AIMS AT UNRAVELING THE MOLECULAR PATHWAYS THROUGH WHICH OUR LIFE STORIES SCULPT GENOMIC FUNCTION TO CONTRIBUTE TO COMPLEX BEHAVIORAL AND SOMATIC PHENOTYPES. 2017 19 2512 30 EPIGENETICS AND PRIMARY BILIARY CIRRHOSIS: A COMPREHENSIVE REVIEW AND IMPLICATIONS FOR AUTOIMMUNITY. PRIMARY BILIARY CIRRHOSIS (PBC) IS A CHRONIC INFLAMMATORY AUTOIMMUNE DISEASE THAT DEVELOPS BASED UPON THE INTERACTION OF GENETIC AND ENVIRONMENTAL FACTORS. RECENT GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE IDENTIFIED DOZENS OF PREDISPOSING VARIANTS INCLUDING HLA, IL12A, AND CTLA4 BUT HAVE BEEN DISAPPOINTED IN IDENTIFYING A "SMOKING GUN." THESE DISCOVERIES HIGHLIGHT THE IMPORTANCE OF THE GENETIC BACKGROUND INVOLVED IN IMMUNOLOGICAL DYSREGULATION. ALTHOUGH CONCORDANCE RATE OF PBC IN MONOZYGOTIC (MZ) TWINS IS AMONG THE HIGHEST REPORTED IN AUTOIMMUNE DISORDERS, INCOMPLETE DISEASE CONCORDANCE IN TWINS ASSOCIATED WITH DIFFERENTIALLY EXPRESSED GENES HAS BEEN DEMONSTRATED. HOWEVER, LITTLE IS UNDERSTOOD ABOUT HOW ENVIRONMENTAL ASPECTS CONTRIBUTE TO THE DISEASE AND WHY MIDDLE-AGED WOMEN ARE MORE SUSCEPTIBLE. AS A RESULT, EPIGENETIC FACTORS, WHICH CONVERT SIGNALS INDICATING ENVIRONMENTAL CHANGES INTO DYNAMIC AND HERITABLE ALTERATIONS OF TRANSCRIPTIONAL POTENTIAL, ARE GETTING INCREASED ATTENTION BY RESEARCHERS IN BOTH BASIC AND CLINICAL STUDIES. AMONG EPIGENETIC MECHANISMS, THE INSTABILITY AND SKEWED GENE EXPRESSION IN THE X CHROMOSOME MAY ACCOUNT FOR THE FEMALE PREPONDERANCE IN PBC. IN ADDITION, TRANSCRIPTIONAL REGULATION OF HISTONE MODIFICATION AND DNA METHYLATION UNDERSCORES POTENTIAL INVOLVEMENT IN DISEASE PATHOGENESIS. HIGH-THROUGHPUT TECHNIQUES ARE BEING USED TO IDENTIFY EPIGENETIC REGULATORS. IN THIS REVIEW, WE ATTEMPT TO OUTLINE RECENT PROGRESS REGARDING EPIGENETICS IN PBC AND OTHER AUTOIMMUNE DISEASES. 2016 20 5222 22 PRIMARY BILIARY CIRRHOSIS: FAMILY STORIES. PRIMARY BILIARY CIRRHOSIS (PBC) IS A CHRONIC IMMUNE-MEDIATED CHOLESTATIC LIVER DISEASE OF UNKNOWN AETIOLOGY WHICH AFFECTS MOSTLY WOMEN IN MIDDLE AGE. FAMILIAL PBC IS WHEN PBC AFFECTS MORE THAN ONE MEMBER OF THE SAME FAMILY, AND DATA SUGGEST THAT FIRST-DEGREE RELATIVES OF PBC PATIENTS HAVE AN INCREASED RISK OF DEVELOPING THE DISEASE. MOST OFTEN, THESE FAMILIAL CLUSTERS INVOLVE MOTHER-DAUGHTER PAIRS, WHICH IS CONSISTENT WITH THE FEMALE PREPONDERANCE OF THE DISEASE. THESE CLUSTERS PROVIDE EVIDENCE TOWARDS A GENETIC BASIS UNDERLYING PBC. HOWEVER, CLUSTERS OF NONRELATED INDIVIDUALS HAVE ALSO BEEN REPORTED, GIVING STRENGTH TO AN ENVIRONMENTAL COMPONENT. TWIN STUDIES HAVE DEMONSTRATED A HIGH CONCORDANCE FOR PBC IN MONOZYGOTIC TWINS AND A LOW CONCORDANCE AMONG DIZYGOTIC TWINS. IN CONCLUSION, STUDIES OF PBC IN FAMILIES CLEARLY DEMONSTRATE THAT GENETIC, EPIGENETIC, AND ENVIRONMENTAL FACTORS PLAY A ROLE IN THE DEVELOPMENT OF THE DISEASE. 2011